GREGORY A GRABOWSKI, M.D.
Medical Practice in Cincinnati, OH
License number
Ohio 35.063485
Category
Medical Practice
Type
Clinical Genetics (M.D.)
Address
Address
3333 Burnet Ave Ml, Cincinnati, OH 45229
Phone
(513) 636-4760
(513) 636-7297 (Fax)
(513) 636-4225
(513) 636-2511 (Fax)
(513) 636-7297 (Fax)
(513) 636-4225
(513) 636-2511 (Fax)
Personal information
See more information about GREGORY A GRABOWSKI at radaris.comName
Address
Phone
2891 Alpine Ter, Cincinnati, OH 45208
1121 Rookwood Ct, Cincinnati, OH 45208
2899 Linwood Ave, Cincinnati, OH 45208
Organization information
See more information about GREGORY A GRABOWSKI at bizstanding.comCincinnati Children's Hospital Medical - Gregory A Grabowski MD
3333 Burnet Ave #4006, Cincinnati, OH 45229
Categories:
Government Contractors, Pediatrics Physicians & Surgeons
Site:
Phone:
(513) 636-4760 (Phone)
Specialties:
Otolaryngology Pediatric MD
Products:
Allergies, Balance Disorders, Ear Infections, ...
Additional:
Neighborhood Locations:, Anderson, Eastgate, Fairfield,Harrison, Mason, Northern Kentuckyand West Chester
Professional information
Dr. Gregory A Grabowski, Cincinnati OH - MD (Doctor of Medicine)
Specialties:
Pediatrics, Clinical Biochemical Genetics, Clinical Genetics, Clinical Molecular Genetics
Address:
3333 Burnet Ave SUITE S, Cincinnati 45229
(513) 636-4760 (Phone), (513) 636-7297 (Fax)
Cincinnati Office
3333 Burnet Ave, Cincinnati 45229
(513) 636-4751 (Phone), (513) 636-8145 (Fax)
(513) 636-4760 (Phone), (513) 636-7297 (Fax)
Cincinnati Office
3333 Burnet Ave, Cincinnati 45229
(513) 636-4751 (Phone), (513) 636-8145 (Fax)
Certifications:
Clinical Biochemical Genetics, 1987, Clinical Genetics, 1987, Clinical Molecular Genetics, 1993, Pediatrics, 1980
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University Of Minnesota Medical School
Graduated: 1974
University Of Minnesota
Graduated: 1975
University Minn Hospital
Graduated: 1976
Graduated: 1979
University Of Minnesota Medical School
Graduated: 1974
University Of Minnesota
Graduated: 1975
University Minn Hospital
Graduated: 1976
Graduated: 1979
Gregory Alex Grabowski, Cincinnati OH
Specialties:
Pediatrician
Address:
3333 Burnet Ave, Cincinnati, OH 45229
Education:
University of Minnesota, Medical School - Doctor of Medicine
University of MN Medical Center-Riverside Campus - Fellowship - Medical Genetics
University of MN Medical Center-Riverside Campus - Residency - Pediatrics
University of MN Medical Center-Riverside Campus - Fellowship - Medical Genetics
University of MN Medical Center-Riverside Campus - Residency - Pediatrics
Board certifications:
American Board of Medical Genetics Certification in Clinical Biochemical Genetics (Medical Genetics), American Board of Medical Genetics Certification in Clinical Genetics (MD) (Medical Genetics), American Board of Pediatrics Certification in Pediatrics
Gregory Alex Grabowski, Cincinnati OH
Specialties:
Pediatrics, General Practice, Medical Genetics, Clinical Biochemical Genetics, Clinical Genetics, M.D.
Work:
Cincinnati Children's Hospital Medical Center
3333 Burnet Ave, Cincinnati, OH 45267
3333 Burnet Ave, Cincinnati, OH 45267
Education:
University of Minnesota, Twin Cities (1974)
Lysosomal Acid Lipase Therapy For Nafld And Related Diseases
US Patent:
2009029, Dec 3, 2009
Filed:
Aug 31, 2006
Appl. No.:
12/065975
Inventors:
Gregory A. Grabowski - Cincinnati OH, US
Assignee:
Childrens Hospital Medical Center - Cincinnati OH
International Classification:
A61K 38/46, A61K 38/16, A61K 38/02, C12P 21/00, C12N 15/63, A61P 1/16
US Classification:
424 946, 514 12, 514 2, 435 691, 435455
Abstract:
The present invention comprises methods and compositions for the treatment or alleviation of NAFLD (non-alcoholic fatty liver disease) and those conditions associated with NAFLD, including fatty liver disease, nonalcoholic steatohepatitis (NASH) and cirrhosis through the use of pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides. This invention is also directed to a combination therapy treatment for treating The Metabolic Syndrome. As part of a combination therapy regime for the treatment of The Metabolic Syndrome, pharmaceutical formulations of lysosomal acid lipase or related proteins and/or polypeptides are used as part of the combination therapy regime for treating NAFLD (and NASH), which comprises one of the conditions constituting The Metabolic Syndrome,
Lipid Hydrolysis Therapy For Atherosclerosis And Related Diseases
US Patent:
2010023, Sep 23, 2010
Filed:
Jan 6, 2010
Appl. No.:
12/683265
Inventors:
Gregory A. Grabowski - Cincinnati OH, US
Hong Du - Cincinnati OH, US
Hong Du - Cincinnati OH, US
International Classification:
A61K 38/46, A61P 9/10, A61P 9/00, A61K 31/7088, C12N 15/09
US Classification:
424 946, 514 44 R, 435455
Abstract:
The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.
Gene-Based Lipid Hydrolysis Therapy For Atherosclerosis And Related Diseases
US Patent:
2007026, Nov 15, 2007
Filed:
Jan 12, 2007
Appl. No.:
11/653147
Inventors:
Gregory Grabowski - Cincinnati OH, US
Hong Du - Cincinnati OH, US
Hong Du - Cincinnati OH, US
International Classification:
A61K 38/46, A61P 43/00
US Classification:
424094600
Abstract:
The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.
Gene-Based Lipid Hydrolysis Therapy For Atherosclerosis And Related Diseases
US Patent:
2004022, Nov 11, 2004
Filed:
Feb 11, 2004
Appl. No.:
10/776797
Inventors:
Gregory Grabowski - Cincinnati OH, US
Hong Du - Cincinnati OH, US
Hong Du - Cincinnati OH, US
International Classification:
A61K038/46
US Classification:
424/094600
Abstract:
The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.
Lipid Hydrolysis Therapy For Atherosclerosis And Related Diseases
US Patent:
2003005, Mar 27, 2003
Filed:
Feb 2, 2001
Appl. No.:
09/775517
Inventors:
Gregory Grabowski - Cincinnati OH, US
Hong Du - Cincinnati OH, US
Hong Du - Cincinnati OH, US
International Classification:
A61K038/46, A61K038/16
US Classification:
424/094600, 514/008000
Abstract:
The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.